Kairos Pharma, Ltd. (KAPA)

NYSEAMERICAN: KAPA · Real-Time Price · USD

1.340

-0.340 (-20.24%)

At close: Sep 18, 2025, 4:00 PM EDT

1.300

-0.040 (-2.99%)

After-hours: Sep 18, 2025, 8:00 PM EDT

Kairos Pharma Employees

As of December 31, 2024, Kairos Pharma had 4 total employees, including 1 full-time and 3 part-time employees.

Employees

4

Change

n/a

Growth

n/a

Revenue / Employee

n/a

Profits / Employee

-$1,177,750

Market Cap

27.80M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	4	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

KAPA News

14 hours ago - Kairos Pharma Announces Positive Interim Efficacy Analysis of Phase 2 Trial of ENV105 in Advanced Prostate Cancer with Median Progression Free Survival of Over One Year - Business Wire
7 days ago - Kairos Pharma Announces Virtual KOL Event to Provide Perspectives on ENV105 Interim Efficacy Results in Advanced Prostate Cancer - Business Wire
15 days ago - Kairos Pharma Announces Presentation of New Phase 1 Data on ENV105 Combination Therapy in Non-Small Cell Lung Cancer at the World Lung Cancer Conference September 6-9, 2025 - Business Wire
16 days ago - Kairos Pharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference - Business Wire
7 weeks ago - CEO.CA's Inside the Boardroom: Kairos Pharma CEO on Phase 2 Safety Data, 165% Stock Move & September Efficacy Timeline - Newsfile Corp
2 months ago - Kairos Pharma Announces Participation and Presentation in the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025 - Business Wire
2 months ago - Why Is Kairos Pharma Stock Surging On Tuesday? - Benzinga
2 months ago - Kairos Pharma Announces Positive Safety Results from Phase 2 Trial of ENV-105 in Advanced Prostate Cancer - Business Wire